share_log

Nova Mentis Applauds Government Decision to Create Rare Disease Advisory Group

Nova Mentis Applauds Government Decision to Create Rare Disease Advisory Group

諾瓦·門蒂斯對政府決定成立罕見病諮詢小組表示讚賞
newsfile ·  2023/11/03 20:30

Vancouver, British Columbia--(Newsfile Corp. - November 3, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased the Canadian government has established a new Implementation Advisory Group (IAG) for drugs for rare diseases, as part of its National Strategy to help facilitate information sharing and improve access and affordability of effective drugs for rare diseases across the country.

不列顛哥倫比亞省溫哥華--(Newsfile Corp.-2023 年 11 月 3 日)- Nova Mentis Life Science Corp.(CSE:NOVA)(FSE:HN3Q)(場外交易代碼:NMLSF)(“NOVA” 或 “公司”), 一家生物技術公司,也是同類首創的基於迷幻藥的神經炎症性疾病療法和輔助診斷領域的全球領導者,很高興加拿大政府成立了新的罕見病藥物實施諮詢小組(IAG),這是其國家戰略的一部分,旨在幫助促進信息共享,改善全國罕見疾病有效藥物的可及性和可負擔性。

As part of this overall investment, the Government of Canada will make available up to $1.4 billion to provinces and territories through bilateral agreements. This funding will help provinces and territories improve access to new and emerging drugs, as well as support enhanced access to existing drugs, early diagnosis, and screening for rare diseases.

作爲總體投資的一部分,加拿大政府將通過雙邊協議向各省和地區提供高達14億加元的資金。這筆資金將幫助各省和地區改善獲得新興藥物的機會,並支持增加獲得現有藥物、早期診斷和罕見疾病篩查的機會。

"NOVA has dedicated its research and drug development efforts to improving quality of life and public health outcomes for those with fragile x syndrome (FXS), a rare disease and the leading genetic cause of autism spectrum disorder (ASD). We applaud the Canadian government for prioritizing families who are dealing with rare diseases and trying to meet the increasing need for effective therapeutic solutions," says CEO, Will Rascan.

“NOVA致力於研究和藥物開發工作,改善脆性x綜合徵(FXS)患者的生活質量和公共衛生結果,脆性x綜合徵是一種罕見的疾病,也是自閉症譜系障礙(ASD)的主要遺傳原因。我們讚揚加拿大政府優先考慮患有罕見疾病的家庭,並努力滿足對有效治療解決方案日益增長的需求。” 首席執行官威爾·拉斯坎說。

NOVA is the first company in the world conducting a human trial investigating the effects of psilocybin on the cognitive and behavioural symptoms associated with FXS. The clinical trial is currently recruiting participants to assess repetitive, oral microdose psilocybin therapy on adults diagnosed with FXS. The Company intends to validate behavioural testing with state-of-the-art diagnostic and therapeutic biomarker technology, and machine learning artificial intelligence (AI).

NOVA是世界上第一家進行人體試驗的公司,該試驗旨在研究迷幻藥對與FXS相關的認知和行爲症狀的影響。該臨床試驗目前正在招募參與者,以評估對被診斷患有FXS的成年人進行的重複口服微劑量迷幻藥治療。該公司打算使用最先進的診斷和治療生物標誌物技術以及機器學習人工智能(AI)來驗證行爲測試。

NOVA is the first biotech company in the world to achieve orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of FXS. Orphan drugs are drugs that are developed specifically to treat rare diseases.

NOVA是世界上第一家在美國和歐盟均獲得孤兒藥認定的生物技術公司,使用迷幻藥治療FXS。孤兒藥是專門爲治療罕見疾病而開發的藥物。

About Nova Mentis Life Science Corp.

關於 Nova Mentis 生命科學公司

Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotech company to achieve orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of fragile X syndrome (FXS).

Nova Mentis Life Science Corp. 是一家總部位於加拿大的生物技術公司,在開發神經炎症性疾病診斷和基於迷幻藥的療法方面處於全球領先地位。Nova是第一家因使用迷幻藥治療脆性X綜合徵(FXS)而在美國和歐盟獲得孤兒藥認定的生物技術公司。

NOVA's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS.

NOVA的目標是診斷和治療醫療需求未得到滿足的使人衰弱的慢性病,例如自閉症譜系障礙(ASD)和FXS。

For further information on the Company, please visit or email info@novamentis.ca.

有關該公司的更多信息,請訪問或發送電子郵件至 info@novamentis.ca。

On Behalf of the Board

代表董事會

Will Rascan, President & CEO
Nova Mentis Life Science Corp.

總裁兼首席執行官威爾·拉斯坎
Nova Mentis 生命科學公司

Phone: 778-819-0244
Toll Free: 1-833-542-5323

電話:778-819-0244
免費電話:1-833-542-5323

Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc

推特:@novamentislsc
Instagram:@novamentislsc
臉書:@novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

加拿大證券交易所及其市場監管機構(該術語在加拿大證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

This news release contains statements that constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

本新聞稿包含構成 “前瞻性陳述” 的陳述。此類前瞻性陳述涉及已知和未知的風險、不確定性和其他因素,這些因素可能導致Nova Mentis Life Science的實際業績、業績或成就或行業發展與此類前瞻性陳述所表達或暗示的預期結果、業績或成就存在重大差異。前瞻性陳述不是歷史事實,通常以 “期望”、“計劃”、“預期”、“相信”、“打算”、“估計”、“項目”、“潛力” 和類似表述來識別,或者事件或條件 “將”、“會”、“可能” 或 “應該” 發生。

To view the source version of this press release, please visit

要查看本新聞稿的源版本,請訪問

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論